Investigation of tear film change after recovery from acute conjunctivitis

Key Laboratory of Ophthalmology, Ministry of Education and Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
Cornea (Impact Factor: 2.04). 08/2007; 26(7):778-81. DOI: 10.1097/ICO.0b013e31806457f8
Source: PubMed


To study the changes of tear film after recovery from acute conjunctivitis.
This study involved 73 eyes of 56 consecutive patients who complained of dry eye after recovery from acute conjunctivitis at the Zhongshan Ophthalmic Center. Excluded were other factors that could affect the stability of the tear film. Tear film breakup time (BUT), Schirmer 1 test (S1T), tear meniscus height (TMH), and fluorescein staining (FL) were performed on both recovered and healthy eyes. The scores were measured at 3, 7, 14, 21, and 30 days after recovery.
Compared with the results of the healthy eyes, most scores of BUT, S1T, TMH, and FL were all abnormal until day 30 after recovery from acute conjunctivitis. BUT decreased at 3, 7, 14, and 21 days (P < 0.05). S1T decreased at 3, 7, and 21 days (P < 0.05). TMH values became less than normal at 3, 7, and 14 days (P < 0.05). FL increased significantly at 7, 14, and 21 days (P < 0.05). At 30 days after recovery, all of the test scores returned to normal (P > 0.05).
During acute conjunctivitis, inflammation and topical therapeutic agents can alter the tear film secretion, resulting in dry eye for nearly 1 month in recovered eyes. To minimize the effect of topical agents to the tear film, individualized treatment instead of frequent instillation of topical agents is recommended for acute conjunctivitis.

13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Until recently, the cause of dry eye syndrome was uncertain and the treatment was palliative. Since discovering that dry eyes are caused by inflammation, there has been an abundance of research focusing on anti-inflammatory therapies, other contributing causes, and better diagnostic testing. This review summarizes some of the interesting published research on ocular surface disease over the past year. The definition of dry eye now highlights the omnipresent symptom of blurry vision. The re-evaluation of ocular surface staining, tear meniscus height, and visual change will allow for a better diagnosis and understanding of dry eyes. Punctal plugs, and oral and topical anti-inflammatory use will strengthen our arsenal against ocular surface disease. Major progress has occurred in the past few years in gaining a better understanding of the etiology of dry eye syndrome, which will inevitably lead to more effective therapeutic options.
    Current opinion in ophthalmology 08/2008; 19(4):287-91. DOI:10.1097/ICU.0b013e3283023d4c · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Acute conjunctivitis is an extremely common condition and can be associated with significant morbidity and economic burden. Despite this, considerable controversy exists pertaining to the prevalence, diagnosis, management, and treatment of the condition. A panel of ophthalmology experts was assembled to review and discuss the current evidence based literature as it pertains to each of these persistent controversies. METHODS AND SCOPE: An acute conjunctivitis round table symposium was convened at the American Academy of Ophthalmology meeting in Atlanta, November 2008. The expert panelists consisted of four academic ophthalmologists in the field of cornea and external disease, whose discussion was informed by an English language literature survey carried out on the PubMed database for the period of January 1972 to October 2008. A narrative summary was generated from the literature review and direct transcription of this event, from which this Review article was developed. FINDINGS AND CONCLUSIONS: Considerable light has been shed on acute microbial conjunctivitis and especially those cases caused by adenovirus. Many of the myths that have perpetuated for years have been debunked by emerging evidence. The advent and the implementation of better diagnostic tools and anti-viral medications will help clinicians to improve their diagnostic accuracy, improve management and treatment decisions, and ultimately benefit patients while saving overall healthcare costs.
    Current Medical Research and Opinion 07/2009; 25(8):1953-61. DOI:10.1185/03007990903038269 · 2.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Numerous brands and types of artificial tears are available on the market for the treatment of dysfunctional tear syndrome. Past literature has focused on comparing the components of these products on patient's clinical improvement. The wide array of products on the market presents challenges to both clinicians and patients when trying to choose between available tear replacement therapies. Different formulations affect patients based on etiology and severity of disease. In order to provide an unbiased comparison between available tear replacement therapies, we conducted a literature review of existing studies and National Institutes of Health clinical trials on commercially available, brand name artificial tears. Outcomes evaluated in each study, as well as the percent of patients showing clinical and symptomatic improvement, were analyzed. Fifty-one studies evaluating different brands of artificial tears, and their efficacy were identified. Out of the 51 studies, 18 were comparison studies testing brand name artificial tears directly against each other. Nearly all formulations of artificial tears provided significant benefit to patients with dysfunctional tear syndrome, but some proved superior to others. From the study data, a recommended treatment flowchart was derived.
    Clinical ophthalmology (Auckland, N.Z.) 07/2014; 8:1419-33. DOI:10.2147/OPTH.S65263